Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2014-05-05

Clinical Trial Update: Study of Macitentan (ACT-064992) on Morbidity and Mortality in Patients With Symptomatic Pulmonary Arterial Hypertension [Phase 3]

View source ↗

Summary

A Phase 3 trial evaluating macitentan in patients with symptomatic pulmonary arterial hypertension has completed, with results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Macitentan (macitentan)

Snippet

Sponsor: Actelion | Conditions: Pulmonary Arterial Hypertension | Phase 3 | Status: COMPLETED | Results posted: 2014-05-05